Troglitazone and tumor inhibition: an evolving concept in the management of systemic malignancies.
Radiation Oncology Journal.2012;30(4):226-227.
Radiation Oncology Journal
2002 (v1, n1) to Present ISSN: 1671-8925
Year of publication
Sort by
DISPLAY OPTIONS
Format:
Per page:
Radiation Oncology Journal.2012;30(4):218-225.
PURPOSE: The relationship between treatment outcomes, alteration of the expression of biological markers, and tumor volume response during radiotherapy (RT) in patients with uterine cervical cancer was analyzed. MATERIALS AND METHODS: Twenty patients with cervical squamous cell carcinoma received definitive RT with (n = 17) or without (n = 3) concurrent chemotherapy. Tumor volumes were measured by three serial magnetic resonance imaging scans at pre-, mid-, and post-RT. Two serial punch biopsies were performed at pre- and mid-RT, and immunohistochemical staining for cyclooxygenase (COX)-2 and epidermal growth factor receptor was performed. The median follow-up duration was 60 months. RESULTS: The median tumor volume response at mid-RT (V2R) was 0.396 (range, 0.136 to 0.983). At mid-RT, an interval increase in the distribution of immunoreactivity for COX-2 was observed in 8 patients, and 6 of them showed poor mid-RT tumor volume response (V2R > or = 0.4). Four (20%) patients experienced disease progression after 10 to 12 months (median, 11 months). All 4 patients had poor mid-RT tumor volume response (p = 0.0867) and 3 of them had an interval increase in COX-2 expression. Overall survival (OS) and progression-free survival (PFS) decreased in patients with V2R > or = 0.4 (p = 0.0291 for both). An interval increase in COX-2 expression at mid-RT was also associated with a decreased survival (p = 0.1878 and 0.1845 for OS and PFS, respectively). CONCLUSION: Poor tumor volume response and an interval increase in COX-2 expression at mid-RT decreased survival outcomes in patients with uterine cervical cancer.
Biomarkers ; Biopsy ; Carcinoma, Squamous Cell ; Cyclooxygenase 2 ; Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Prostaglandin-Endoperoxide Synthases ; Receptor, Epidermal Growth Factor ; Tumor Burden ; Uterine Cervical Neoplasms
Biomarkers ; Biopsy ; Carcinoma, Squamous Cell ; Cyclooxygenase 2 ; Disease Progression ; Disease-Free Survival ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Prostaglandin-Endoperoxide Synthases ; Receptor, Epidermal Growth Factor ; Tumor Burden ; Uterine Cervical Neoplasms
Postoperative chemoradiotherapy in high risk locally advanced gastric cancer.
Radiation Oncology Journal.2012;30(4):213-217.
PURPOSE: To evaluate treatment outcome of patients with high risk locally advanced gastric cancer after postoperative chemoradiotherapy. MATERIALS AND METHODS: Between May 2003 and May 2012, thirteen patients who underwent postoperative chemoradiotherapy for gastric cancer with resection margin involvement or adjacent structure invasion were retrospectively analyzed. Concurrent chemotherapy was administered in 10 patients. Median dose of radiation was 50.4 Gy (range, 45 to 55.8 Gy). RESULTS: The median follow-up duration for surviving patients was 48 months (range, 5 to 108 months). The 5-year overall survival rate was 42% and the 5-year disease-free survival rate was 28%. Major pattern of failure was peritoneal seeding with 46%. Locoregional recurrence was reported in only one patient. Grade 2 or higher gastrointestinal toxicity occurred in 54% of the patients. However, there was only one patient with higher than grade 3 toxicity. CONCLUSION: Despite reported suggested role of adjuvant radiotherapy with combination chemotherapy in gastric cancer, only very small portion of the patients underwent the treatment. Results from this study show that postoperative chemoradiotherapy provided excellent locoregional control with acceptable and manageable treatment related toxicity in patients with high risk locally advanced gastric cancer. Thus, postoperative chemoradiotherapy may improve treatment result in terms of locoregional control in these high risk patients. However, as these findings are based on small series, validation with larger cohort is suggested.
Chemoradiotherapy ; Chemoradiotherapy, Adjuvant ; Cohort Studies ; Disease-Free Survival ; Drug Therapy, Combination ; Follow-Up Studies ; Humans ; Radiotherapy, Adjuvant ; Recurrence ; Retrospective Studies ; Seeds ; Stomach Neoplasms ; Survival Rate ; Treatment Outcome
Chemoradiotherapy ; Chemoradiotherapy, Adjuvant ; Cohort Studies ; Disease-Free Survival ; Drug Therapy, Combination ; Follow-Up Studies ; Humans ; Radiotherapy, Adjuvant ; Recurrence ; Retrospective Studies ; Seeds ; Stomach Neoplasms ; Survival Rate ; Treatment Outcome
Radiation Oncology Journal.2012;30(4):205-212.
PURPOSE: To evaluate the effect of pelvic radiotherapy (RT) in patients with stage IV rectal cancer treated with resection of primary tumor with or without metastasectomy. MATERIALS AND METHODS: Medical records of 112 patients with stage IV rectal cancer treated with resection of primary tumor between 1990 and 2011 were retrospectively reviewed. Fifty-nine patients received synchronous or staged metastasectomy whereas fifty-three patients did not. Twenty-six patients received pelvic radiotherapy. RESULTS: Median overall survival (OS), locoregional recurrence-free survival (LRFS), and progression-free survival (PFS) of all patients was 27, 70, and 11 months, respectively. Pathologic T (pT), N (pN) classification and complete metastasectomy were statistically significant factors in OS (p = 0.040, 0.020, and 0.002, respectively). RT did not improve OS or LRFS. There were no significant factors in LRFS. pT and pN classification were also significant prognostic factors in PFS (p = 0.010 and p = 0.033, respectively). In the subgroup analysis, RT improved LRFS in patients with pT4 disease (p = 0.026). The locoregional failure rate of the RT group and the non-RT group were 23.1% and 33.7%, showing no difference in the failure pattern of both groups (p = 0.260). CONCLUSION: Postoperative pelvic RT did not improve LRFS of all metastatic rectal cancer patients; however, it can be recommended to patients with pT4 disease. A complete resection of metastatic masses should be performed if possible.
Disease-Free Survival ; Humans ; Medical Records ; Metastasectomy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Rectal Neoplasms ; Retrospective Studies
Disease-Free Survival ; Humans ; Medical Records ; Metastasectomy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Rectal Neoplasms ; Retrospective Studies
Radiation Oncology Journal.2012;30(4):197-204.
PURPOSE: To analyze the outcomes of chemoradiotherapy for extrahepatic bile duct (EHBD) cancer patients who underwent R2 resection or bypass surgery and to identify prognostic factors affecting clinical outcomes, especially in terms of molecular biomarkers. MATERIALS AND METHODS: Medical records of 21 patients with EHBD cancer who underwent R2 resection or bypass surgery followed by chemoradiotherapy from May 2001 to June 2010 were retrospectively reviewed. All surgical specimens were re-evaluated by immunohistochemical staining using phosphorylated protein kinase B (pAKT), CD24, matrix metalloproteinase 9 (MMP9), survivin, and beta-catenin antibodies. The relationship between clinical outcomes and immunohistochemical results was investigated. RESULTS: At a median follow-up of 20 months, the actuarial 2-year locoregional progression-free, distant metastasis-free and overall survival were 37%, 56%, and 54%, respectively. On univariate analysis using clinicopathologic factors, there was no significant prognostic factor. In the immunohistochemical staining, cytoplasmic staining, and nuclear staining of pAKT was positive in 10 and 6 patients, respectively. There were positive CD24 in 7 patients, MMP9 in 16 patients, survivin in 8 patients, and beta-catenin in 3 patients. On univariate analysis, there was no significant value of immunohistochemical results for clinical outcomes. CONCLUSION: There was no significant association between clinical outcomes of patients with EHBD cancer who received chemoradiotherapy after R2 resection or bypass surgery and pAKT, CD24, MMP9, survivin, and beta-catenin. Future research is needed on a larger data set or with other molecular biomarkers.
Antibodies ; beta Catenin ; Bile Ducts, Extrahepatic ; Biomarkers ; Chemoradiotherapy ; Cytoplasm ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Matrix Metalloproteinase 9 ; Medical Records ; Proto-Oncogene Proteins c-akt ; Retrospective Studies
Antibodies ; beta Catenin ; Bile Ducts, Extrahepatic ; Biomarkers ; Chemoradiotherapy ; Cytoplasm ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Matrix Metalloproteinase 9 ; Medical Records ; Proto-Oncogene Proteins c-akt ; Retrospective Studies
Radiation Oncology Journal.2012;30(4):189-196.
PURPOSE: To investigate the safety of high dose hypofractionated radiotherapy (RT) in patients with small hepatocellular carcinoma (HCC) in terms of liver volumetric changes and clinical liver function. MATERIALS AND METHODS: We retrospectively reviewed 16 patients with small HCC who were treated with high dose hypofractionated RT between 2006 and 2009. The serial changes of the liver volumetric parameter were analyzed from pre-RT and follow-up (FU) computed tomography (CT) scans. We estimated linear time trends of whole liver volume using a linear mixed model. The serial changes of the Child-Pugh (CP) scores were also analyzed in relation to the volumetric changes. RESULTS: Mean pre-RT volume of entire liver was 1,192.2 mL (range, 502.6 to 1,310.2 mL) and mean clinical target volume was 14.7 mL (range, 1.56 to 70.07 mL). Fourteen (87.5%) patients had 4 FU CT sets and 2 (12.5%) patients had 3 FU CT sets. Mean interval between FU CT acquisition was 2.5 months. After considering age, gender and the irradiated liver volume as a fixed effects, the mixed model analysis confirmed that the change in liver volume is not significant throughout the time course of FU periods. Majority of patients had a CP score change less than 2 except in 1 patient who had CP score change more than 3. CONCLUSION: The high dose hypofractionated RT for small HCC is relatively safe and feasible in terms of liver volumetric changes and clinical liver function.
Carcinoma, Hepatocellular ; Follow-Up Studies ; Humans ; Liver ; Retrospective Studies
Carcinoma, Hepatocellular ; Follow-Up Studies ; Humans ; Liver ; Retrospective Studies
Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy.
Radiation Oncology Journal.2012;30(4):182-188.
PURPOSE: For recurrent esophageal cancer after primary definitive radiotherapy, no general treatment guidelines are available. We evaluated the toxicities and clinical outcomes of re-irradiation (re-RT) for recurrent esophageal cancer. MATERIALS AND METHODS: We analyzed 10 patients with recurrent esophageal cancer treated with re-RT after primary definitive radiotherapy. The median time interval between primary radiotherapy and re-RT was 15.6 months (range, 4.8 to 36.4 months). The total dose of primary radiotherapy was a median of 50.4 Gy (range, 50.4 to 63.0 Gy). The total dose of re-RT was a median of 46.5 Gy (range, 44.0 to 50.4 Gy). RESULTS: The median follow-up period was 4.9 months (range, 2.6 to 11.4 months). The tumor response at 3 months after the end of re-RT was complete response (n = 2), partial response (n = 1), stable disease (n = 2), and progressive disease (n = 5). Grade 5 tracheoesophageal fistula developed in three patients. The time interval between primary radiotherapy and re-RT was less than 12 months in two of these three patients. Late toxicities included grade 1 dysphagia (n = 1). CONCLUSION: Re-RT of recurrent esophageal cancer after primary radiotherapy can cause severe toxicity.
Deglutition Disorders ; Esophageal Neoplasms ; Follow-Up Studies ; Humans ; Tracheoesophageal Fistula
Deglutition Disorders ; Esophageal Neoplasms ; Follow-Up Studies ; Humans ; Tracheoesophageal Fistula
Radiation Oncology Journal.2012;30(4):173-181.
PURPOSE: To evaluate the prognostic value of preoperative neck lymph node (LN) assessment with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET), computed tomography (CT), and magnetic resonance imaging (MRI) in oral cavity squamous cell carcinoma (OSCC) patients with pathologically positive LN. MATERIALS AND METHODS: In total, 47 OSCC patients with pathologically positive LN were retrospectively reviewed with preoperative 18F-FDG PET and CT/MRI. All patients underwent surgical resection, neck dissection and postoperative adjuvant radiotherapy and/or chemotherapy between March 2002 and October 2010. Histologic correlation was performed for findings of 18F-FDG PET and CT/MRI. RESULTS: Thirty-six (76.6%) of 47 cases were correctly diagnosed with neck LN metastasis by 18F-FDG PET and 32 (68.1%) of 47 cases were correctly diagnosed by CT/MRI. Follow-up ranged from 20 to 114 months (median, 56 months). Clinically negative nodal status evaluated by 18F-FDG PET or CT/MRI revealed a trend toward better clinical outcomes in terms of overall survival, disease-free survival, local recurrence-free survival, regional nodal recurrence-free survival, and distant metastasis-free survival rates even though the trends were not statistically significant. However, there was no impact of neck node standardized uptake value (SUVmax) on clinical outcomes. Notably, SUVmax showed significant correlation with tumor size in LN (p < 0.01, R2 = 0.62). PET and CT/MRI status of LN also had significant correlation with the size of intranodal tumor deposit (p < 0.05, R2 = 0.37 and p < 0.01, R2 = 0.48, respectively). CONCLUSION: 18F-FDG PET and CT/MRI at the neck LNs might improve risk stratification in OSCC patients with pathologically positive neck LN in this study, even without significant prognostic value of SUVmax.
Carcinoma, Squamous Cell ; Disease-Free Survival ; Electrons ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Humans ; Lymph Nodes ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Magnetics ; Magnets ; Mouth ; Neck ; Neck Dissection ; Neoplasm Metastasis ; Positron-Emission Tomography ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate ; Tomography, X-Ray Computed
Carcinoma, Squamous Cell ; Disease-Free Survival ; Electrons ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Humans ; Lymph Nodes ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Magnetics ; Magnets ; Mouth ; Neck ; Neck Dissection ; Neoplasm Metastasis ; Positron-Emission Tomography ; Radiotherapy, Adjuvant ; Retrospective Studies ; Survival Rate ; Tomography, X-Ray Computed
Radiation Oncology Journal.2012;30(4):165-172.
PURPOSE: To retrospectively evaluate the outcome and toxicity of total lymphoid irradiation (TLI) based conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in severe aplastic anemia (SAA) patients who experienced an engraftment failure from prior HSCT or were heavily transfused. MATERIALS AND METHODS: Between 1995 and 2006, 20 SAA patients received TLI for conditioning of HSCT. All patients were multi-transfused or had long duration of disease. Fifteen (75%) patients had graft failure from prior HSCT. In 18 (90%) patients, the donors were human leukocyte antigen identical siblings. The stem cell source was the peripheral blood stem cell in 15 (75%) patients. The conditioning regimen was composed of antithymocyte globulin plus TLI with a median dose of 750 cGy in 1 fraction. The graft-versus-host disease (GVHD) prophylaxis used cyclosporine with methotrexate. RESULTS: With a median follow-up of 10.8 years, graft failures developed in 6 patients. Among them, 3 patients received their third HSCT to be engrafted finally. The Kaplan-Meier overall survival rate was 85.0% and 83.1% at 5 and 10 years, respectively. The incidence of acute and chronic GVHD was 20% and 20%, respectively. None of the patients have developed a malignancy after HSCT. CONCLUSION: In our study, TLI based conditioning in allogeneic HSCT was feasible with acceptable rates of GVHD in SAA patients who experienced graft failure from prior HSCT or was at a high risk of graft rejection. We achieved relatively better results of engraftment and survival with a long term follow-up.
Anemia, Aplastic ; Antilymphocyte Serum ; Cyclosporine ; Follow-Up Studies ; Graft Rejection ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells ; Humans ; Incidence ; Leukocytes ; Lymphatic Irradiation ; Retrospective Studies ; Siblings ; Stem Cells ; Survival Rate ; Tissue Donors ; Transplants
Anemia, Aplastic ; Antilymphocyte Serum ; Cyclosporine ; Follow-Up Studies ; Graft Rejection ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells ; Humans ; Incidence ; Leukocytes ; Lymphatic Irradiation ; Retrospective Studies ; Siblings ; Stem Cells ; Survival Rate ; Tissue Donors ; Transplants
Radiation Oncology Journal.2016;34(2):156-159. doi:10.3857/roj.2016.01732
Although carbohydrate antigen (CA) 19-9 is a useful tumor marker for pancreatic cancer, it can also become elevated from a variety of benign and malignant conditions. Herein we describe an unusual presentation of elevated CA 19-9 in an asymptomatic patient who had previously undergone adjuvant chemotherapy and radiation therapy for resected early stage pancreatic cancer. The rise in CA 19-9 might be due to delayed radiation-induced inflammation related to previous intra-abdominal radiation therapy with or without radiation recall induced by gemcitabine. After treatment with corticosteroids the CA 19-9 level decreased to normal, and the patient has not developed any evidence of recurrent cancer to date.
Adrenal Cortex Hormones ; Biomarkers, Tumor ; CA-19-9 Antigen ; Chemotherapy, Adjuvant ; Humans ; Inflammation* ; Pancreatic Neoplasms* ; Radiodermatitis
Adrenal Cortex Hormones ; Biomarkers, Tumor ; CA-19-9 Antigen ; Chemotherapy, Adjuvant ; Humans ; Inflammation* ; Pancreatic Neoplasms* ; Radiodermatitis
Country
Republic of Korea
Publisher
ElectronicLinks
Editor-in-chief
Abbreviation
Radiation Oncology Journal
Vernacular Journal Title
ISSN
2234-1900
EISSN
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
Description
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)